Core Viewpoint - The emergence of GLP-1 receptor agonists, such as semaglutide and tirzepatide, has transformed obesity treatment, enabling rapid weight loss of 15%-20%. However, approximately 50% of obese patients discontinue these medications within a year, leading to significant weight regain and the need to understand post-medication weight changes [6][10]. Research Background: Current Status and Challenges in Obesity Treatment - Nearly 2 billion adults globally are affected by overweight or obesity, which significantly increases the risk of various complications and premature death. Behavioral weight management programs (BWMP) have traditionally been the cornerstone of obesity treatment, focusing on low-calorie diets and increased physical activity. The introduction of new weight loss medications is changing the treatment landscape [6][5]. Research Methodology: Rigorous Evidence Synthesis - The research team systematically reviewed seven databases and trial registries, including 37 studies with 9,341 participants. The average treatment duration was 39 weeks, with an average follow-up of 32 weeks post-medication. Various weight loss medications were analyzed, focusing on both weight changes and cardiovascular metabolic markers [8][7]. Key Findings: Dual Regain of Weight and Health Indicators - On average, participants lost 8.3 kg during medication use, but weight began to rebound post-discontinuation at a rate of 0.4 kg per month, leading to a full return to baseline weight in approximately 1.7 years. Newer medications like semaglutide and tirzepatide showed even faster rebound rates of 0.8 kg per month, returning to baseline in about 1.5 years. Cardiovascular metabolic benefits also diminished within 1.4 years after stopping medication [10][4]. Comparative Analysis: Differences Between Medication and Behavioral Interventions - While medication resulted in a greater average weight loss of 3.2 kg, the rebound rate was significantly faster compared to behavioral interventions, which had a rebound rate of only 0.1 kg per month, taking about 3.9 years to return to baseline weight. This indicates that behavioral interventions may equip participants with sustainable weight management skills, unlike medication, which primarily reduces hunger and increases satiety [12][14]. Insights and Recommendations: Rational Perspective on Weight Loss Medications - The research emphasizes that obesity is a chronic relapsing disease that may require long-term treatment for sustained health benefits. Evidence suggests that continuous use of semaglutide for four years can successfully maintain weight loss. Given the high discontinuation rates of weight loss medications, it is crucial to recognize that these drugs alone may not suffice for long-term weight control. Sustainable healthy lifestyle changes remain fundamental in obesity prevention and treatment [15][16].

Core Viewpoint - The article focuses on individuals who successfully lose weight through lifestyle changes but experience weight regain, highlighting the challenges of long-term obesity management and effective strategies to prevent weight rebound [7][11]. Summary by Sections Weight Rebound Challenges - A systematic review and meta-analysis indicate that approximately 75% of individuals who lose an average of 14 kg through lifestyle interventions will regain weight within about five years [7]. - Weight rebound is not limited to those who undergo lifestyle changes; individuals who stop medication or have undergone weight loss surgery also face similar challenges [7]. Mechanisms Behind Weight Rebound - Research from 2022 shows that macrophages in adipose tissue produce elevated levels of lipopolysaccharide-induced cytokines, contributing to a "fat memory" that increases the risk of weight regain [9]. - A 2023 study published in *Nature Metabolism* reveals that obese individuals have a diminished brain response to nutritional stimuli, which may be a key factor in weight rebound after successful weight loss [9]. Strategies to Reduce Weight Rebound Risk 1. **Dietary Adjustments** - High-protein, low glycemic index (GI), or low glycemic load diets can help reduce the risk of weight rebound. Anti-inflammatory dietary patterns are also recommended [11]. 2. **Increased Physical Activity** - Regular exercise improves leptin sensitivity, enhances sympathetic nervous activity, reduces hunger, and promotes fat oxidation, which aids in maintaining weight loss [12]. 3. **Pharmacological and Biomedical Interventions** - In addition to diet and exercise, pharmacological treatments and other biomedical methods are suggested to prevent weight rebound by reducing adipose tissue mass [13]. 4. **Individualized Management and Ongoing Research** - The occurrence of weight rebound is influenced by multiple factors, necessitating further scientific research to explore more effective long-term management strategies [14].

Core Viewpoint - The article discusses the rising obesity rates in China and the global implications of obesity, highlighting the transformative role of GLP-1 medications like semaglutide in the weight loss market, while also addressing the challenges of medication adherence and the reasons for discontinuation of use [4][6][20]. Group 1: Obesity Statistics and Economic Impact - China has the highest number of overweight and obese individuals globally, with over 530 million adults affected, including approximately 100 million classified as obese [4] - By 2030, it is projected that the number of overweight adults in China will reach 540 million, and the number of obese individuals will increase to 150 million, representing a 2.8-fold and 7.5-fold increase from 2000, respectively [4] - The global obesity rate is expected to rise to 25% by 2035, up from 14% in 2020, with obesity impacting global economic productivity equivalent to 3.6% of the US GDP, leading to indirect costs as high as $1.24 trillion [4] Group 2: Medication Adherence and Discontinuation - A study published in the journal "Obesity" found that semaglutide has the highest adherence rate among weight loss medications, with 63% of users still on the medication after three months, 56% after six months, and 40% after one year [6] - Common side effects of GLP-1 medications include nausea, diarrhea, and vomiting, which may lead to discontinuation; 17% of patients reported nausea even at low doses of semaglutide [9] - Supply issues have plagued semaglutide since 2022, contributing to challenges in patient adherence [10] Group 3: Effects of Discontinuation - A clinical trial indicated that participants who stopped semaglutide after an initial 20-week treatment regained an average of 6.9% of their body weight, while those who continued the medication lost an additional 7.9% [7] - Participants who maintained semaglutide use and lifestyle changes lost an average of 17.3% of their body weight over 68 weeks, while those who stopped regained about two-thirds of their weight [7] Group 4: Reasons for Stopping Medication - Patients may stop using semaglutide after reaching their target weight or due to a plateau in weight loss, mistakenly believing the medication is no longer effective [12][15] - Gradual dose reduction is recommended to mitigate increased hunger sensations that may occur after stopping the medication [15] Group 5: Importance of Lifestyle Changes - Effective weight loss requires a combination of medication and lifestyle changes; reliance solely on medication is insufficient [16] - Regular exercise is crucial for preventing weight regain and improving overall health [19] Group 6: Long-term Use of Semaglutide - Studies show that continuous use of semaglutide over two years can lead to a weight reduction of 15.2% compared to placebo, with 77.1% of patients losing at least 5% of their body weight [20] - Obesity is a chronic condition requiring ongoing management, similar to other chronic diseases, emphasizing the need for long-term medication use [21]

Core Viewpoint - The article focuses on individuals who successfully lose weight through lifestyle changes but experience weight regain, highlighting the challenges of long-term obesity management and effective strategies to prevent weight rebound [7]. Summary by Sections Weight Regain Challenges - A systematic review and meta-analysis indicate that approximately 75% of individuals who lose an average of 14 kg through lifestyle interventions will experience weight regain within about 5 years [7]. - Weight rebound is not limited to those who undergo lifestyle changes; individuals who have weight loss surgery or stop medication also face similar challenges [7]. - There is significant variability in weight regain among individuals, with some maintaining weight loss for years while others revert to their original weight within months [7]. Physiological Mechanisms - A 2022 study found that macrophages in adipose tissue produce elevated levels of lipopolysaccharides and cytokines during obesity, which remain high post-weight loss, indicating a "fat memory" that increases the risk of weight regain [9]. - A 2023 study published in *Nature Metabolism* revealed that obese individuals have a diminished brain response to nutritional stimuli, which may contribute to long-term adaptations that lead to weight rebound after weight loss [9]. Strategies to Reduce Weight Rebound Risk 1. **Dietary Adjustments** - High-protein, low glycemic index (GI), or low glycemic load diets can help reduce the risk of weight rebound. Foods that promote satiety do not lead to significant differences in weight rebound when caloric intake is controlled [11]. - An anti-inflammatory dietary pattern, including olive oil, tomatoes, leafy greens, nuts, fatty fish, and fruits, while minimizing refined carbohydrates, fried foods, sugary drinks, red meat, and margarine, may also lower rebound probabilities [11]. 2. **Increased Physical Activity** - Regular exercise improves leptin sensitivity, enhances sympathetic nervous activity, reduces hunger, increases satiety, promotes fat oxidation, and preserves muscle mass, all of which contribute to maintaining weight loss [12]. - While the effectiveness of different exercise types (aerobic, high-intensity interval, resistance training) is still debated, higher overall activity levels correlate with better weight maintenance outcomes [12]. 3. **Pharmacological and Biomedical Interventions** - In addition to diet and exercise, pharmacological treatments and other biomedical strategies are recommended to prevent weight rebound, such as reducing adipose tissue mass for more stable weight control [13]. 4. **Individualized Management and Ongoing Research** - Weight rebound is influenced by multiple factors, including diet, exercise, medication, and biomedical interventions. Future research should focus on different populations to explore more effective long-term management strategies [14]. - Overall, weight rebound is a common challenge in weight loss journeys, but through scientific dietary practices, regular exercise, appropriate pharmacological interventions, and continuous individualized management, more sustainable weight loss outcomes can be achieved [14].

Core Viewpoint - Obesity is a health condition associated with excess fat accumulation, leading to various complications and comorbidities. GLP-1 receptor agonists have been approved for treating obesity and type 2 diabetes, demonstrating effectiveness in appetite reduction and food intake decrease [2][3]. Group 1: Efficacy of GLP-1 Receptor Agonists - GLP-1 receptor agonists like semaglutide and tirzepatide have shown weight loss of 15%-20% compared to placebo over 68 to 72 weeks [3]. - Despite their effectiveness, about half of the patients discontinue treatment within the first year due to gastrointestinal side effects and high costs [3]. - Weight regain is common after stopping GLP-1 receptor agonists, emphasizing the need for continued use for sustained benefits [5][6]. Group 2: Weight Maintenance Challenges - A clinical trial indicated that participants who switched from semaglutide to placebo regained an average of 6.9% of their body weight, while those who continued treatment lost an additional 7.9% [6]. - After one year of stopping semaglutide, 18% of patients regained their lost weight, and 26% regained more than 25% of their weight [6]. Group 3: Treatment Duration and Guidelines - Patients should not stop medication before it takes effect and should continue for at least 12 weeks to see significant results. If effective, continuation for 9 months to 1 year is recommended [7]. - After three months of semaglutide use, patients typically experience a weight loss of 5.9%, increasing to 10.9% after six months [7]. Group 4: Strategies for Weight Management Post-Treatment - To prevent weight regain after stopping medication, patients should monitor appetite and weight closely, maintaining healthy eating habits and regular exercise [14]. - Dietary changes, such as reducing high-calorie foods and increasing protein and fiber intake, are crucial for weight maintenance [15]. - Incorporating strength training alongside aerobic exercise can enhance metabolic rate and support long-term weight loss [17]. Group 5: Importance of Sleep - Insufficient sleep can disrupt metabolic regulation, increasing hunger hormone levels and decreasing satiety hormone levels, leading to increased calorie intake [18]. - Adults are recommended to aim for 7-9 hours of sleep per night for optimal health and weight management [18].

Core Insights - The article emphasizes that weight loss is not merely about the numbers on a scale but involves significant changes in the underlying fat tissue, which can reverse aging processes in metabolic cells [7][9][10]. Group 1: Research Findings - A study published in July 2025 in *Nature* revealed that obesity accelerates the aging of metabolic and vascular cells within fat tissue, but weight loss can significantly reverse this premature aging phenomenon [7]. - The research highlights that while weight loss reduces inflammation, the memory of immune responses remains, posing a risk for potential weight regain [10][12]. - The study focused on subcutaneous abdominal fat, which is linked to central obesity and metabolic disorders like type 2 diabetes and hyperlipidemia, suggesting that understanding its dynamic changes is crucial for unlocking the health benefits of weight loss [8]. Group 2: Mechanisms of Weight Loss - Weight loss not only leads to a decrease in body weight but also transforms the structure and function of fat tissue towards a healthier state, driven by complex immune regulatory mechanisms [10][15]. - Despite improvements in local inflammation and reductions in inflammatory markers, some macrophages remain in a pre-activated state, which could trigger inflammation again upon encountering new stimuli, potentially leading to weight regain [10][15]. Group 3: Long-term Effects of Obesity - Research indicates that even after successful weight loss, changes at the cellular level persist, with fat cells retaining characteristics from the obese state, which may lead to faster fat accumulation upon re-exposure to high-fat diets [15][19]. - Animal studies corroborate these findings, showing that fat tissue in obese mice retains a form of epigenetic memory that influences their metabolic responses even after weight loss [19]. Group 4: Implications for Weight Management - The persistent "obesity memory" in fat tissue and immune cells suggests that weight management strategies must consider these long-term changes to prevent weight regain and associated metabolic diseases [19]. - The article underscores the importance of developing comprehensive weight management approaches that address both the physiological and psychological aspects of obesity [19].

Core Insights - The article emphasizes that weight loss is not merely about the numbers on the scale but involves significant changes in the underlying fat tissue, which can reverse aging processes in metabolic cells [7][9][10] - It highlights the persistent "memory" of inflammation in immune cells and fat tissue, which can lead to weight regain after initial weight loss [10][15][19] Group 1: Research Findings - A study published in July 2025 in *Nature* revealed that obesity accelerates the aging of metabolic and vascular cells in fat tissue, while weight loss can significantly reverse this premature aging [7] - The research indicates that while weight loss reduces inflammation, the immune system retains a "memory" of the previous obese state, which may contribute to weight regain [10][12] - The study focused on subcutaneous abdominal fat, linking it to metabolic disorders such as type 2 diabetes and hyperlipidemia, suggesting that understanding its dynamics is key to unlocking the health benefits of weight loss [8] Group 2: Mechanisms of Weight Loss - Weight loss not only reduces body weight but also transforms the structure and function of fat tissue towards a healthier state, involving complex immune regulatory mechanisms [10][15] - Despite improvements in local inflammation and reduced expression of inflammatory factors, some macrophages remain in a pre-activated state, posing a risk for future inflammation and weight regain [10][12] - Research shows that even two years after successful weight loss, fat cells retain changes from the obese state, leading to increased absorption of sugars and fats, which can accelerate fat accumulation upon re-exposure to high-calorie diets [15][19] Group 3: Experimental Evidence - Animal studies using C57BL/6J mice demonstrated that after weight loss, the fat tissue still exhibited increased macrophage presence and persistent gene expression changes associated with obesity [17][19] - The findings indicate that these "obesity memories" in fat cells can lead to abnormal responses to metabolic stimuli, contributing to the risk of weight regain and the recurrence of obesity-related metabolic diseases [19]

Core Viewpoint - Obesity is a health condition associated with excess fat accumulation, leading to various complications and comorbidities. GLP-1 receptor agonists have been approved for treating obesity and type 2 diabetes, demonstrating effectiveness in appetite reduction and food intake decrease [2][3]. Group 1: Efficacy of GLP-1 Receptor Agonists - GLP-1 receptor agonists like semaglutide and tirzepatide have shown weight loss of 15%-20% compared to placebo after 68 and 72 weeks of treatment, respectively [3]. - Despite their effectiveness, about half of the patients discontinue treatment within the first year due to gastrointestinal side effects and high costs [3]. - A clinical trial indicated that participants who continued semaglutide lost an average of 17.3% of their weight over 68 weeks, while those who switched to placebo regained approximately 6.9% of their weight [6]. Group 2: Challenges in Weight Maintenance - One of the biggest challenges in weight loss is maintaining the results, as many individuals experience weight regain after stopping treatment. Studies show that discontinuation of GLP-1 receptor agonists often leads to weight gain [5]. - After stopping semaglutide, 18% of patients regained their previous weight, and 26% regained more than 25% of their lost weight within a year [6]. Group 3: Treatment Duration and Strategies - It is recommended to continue treatment for at least 12 weeks before assessing effectiveness, with a suggested duration of 9 months to 1 year for consolidation therapy if significant weight loss is observed [7]. - Initial weeks of semaglutide treatment may lead to increased satiety and reduced food intake, although mild side effects like nausea may occur [10][11]. Group 4: Discontinuation and Monitoring - Gradual dose reduction is advised when discontinuing semaglutide to mitigate increased hunger sensations, especially for non-diabetic patients [12]. - Patients are encouraged to monitor their appetite and weight closely after stopping medication, and to maintain healthy eating habits and regular exercise to prevent weight rebound [14]. Group 5: Strategies to Prevent Weight Regain - Key strategies to prevent weight regain include altering dietary habits by reducing high-calorie foods and increasing protein and fiber intake to enhance metabolism [15]. - Incorporating strength training alongside aerobic exercises can help maintain weight loss by increasing muscle mass and metabolic rate [17]. - Adequate sleep is crucial for metabolic regulation, with 7-9 hours of sleep recommended for optimal health [18].

Core Viewpoint - Obesity is a health condition associated with excess fat accumulation, leading to various complications and comorbidities. GLP-1 receptor agonists have been developed and approved for obesity treatment, demonstrating effectiveness in appetite reduction and weight loss [1][2][4]. Summary by Sections Treatment Efficacy - GLP-1 receptor agonists, such as semaglutide and tirzepatide, have shown weight loss of 15%-20% after 68 to 72 weeks compared to placebo [2]. - A clinical trial indicated that participants lost an average of 10.6% of their body weight during 20 weeks of semaglutide treatment, with those continuing the drug losing an additional 7.9% over 48 weeks [5]. Challenges in Weight Maintenance - One of the biggest challenges in weight loss is maintaining the results, as many individuals experience weight regain after stopping treatment. Studies show that stopping GLP-1 receptor agonists can lead to significant weight gain [4][5]. - After one year of stopping semaglutide, approximately two-thirds of the weight lost can be regained [5]. Medication Management - It is recommended to continue GLP-1 receptor agonist treatment for at least 12 weeks to see significant effects, with a suggested continuation of 9 months to 1 year for consolidation [6]. - Users may experience increased satiety and reduced food intake initially, with weight loss typically ranging from 0.5 to 2 pounds per week [9]. Discontinuation Strategies - Gradual dose reduction is advised when stopping the medication to mitigate increased hunger, with specific recommendations for both non-diabetic and diabetic patients [10][12]. - Maintaining healthy eating habits and regular exercise is crucial post-discontinuation to prevent weight rebound [12]. Dietary and Lifestyle Recommendations - Key strategies to prevent weight regain include altering dietary habits by reducing high-calorie foods and increasing protein and fiber intake [13]. - Incorporating strength training and ensuring adequate sleep (7-9 hours per night) are also essential for maintaining weight loss and improving metabolic health [15].

Core Viewpoint - The article discusses the challenges of weight management and the phenomenon of weight regain after dieting, emphasizing the need for innovative solutions in the weight loss industry to combat this issue [1][2][6]. Group 1: Weight Management Initiatives - The National Health Commission of China has launched a three-year "Weight Management Year" initiative aimed at reducing weight and controlling chronic diseases [1]. - The concept of "metabolic memory" explains why individuals often regain weight after losing it, as the body tends to remember previous weight levels [2][6]. Group 2: Current Market Dynamics - The weight loss market is seeing significant sales, with drugs like semaglutide generating annual revenues of $28.3 billion [3]. - Major pharmaceutical companies, including Novo Nordisk and Eli Lilly, are focusing on developing new mechanisms and improving existing products to address muscle loss and weight regain during weight loss [2][10]. Group 3: Challenges in Weight Loss - Many weight loss methods lead to muscle loss, which can decrease the basal metabolic rate and exacerbate weight regain after stopping treatment [10]. - A study published in the Journal of the American Medical Association indicated that participants who stopped taking the weight loss drug tirzepatide regained an average of 14% of their lost weight within a year [8]. Group 4: Innovative Solutions and Research - Companies are exploring new drug targets and combination therapies to enhance weight loss while preserving muscle mass [10][11]. - The UK company NodThera is investigating an anti-inflammatory approach to weight loss, which has attracted interest from major players like Novo Nordisk [11]. Group 5: Long-term Weight Management Strategies - Experts recommend sustainable lifestyle changes, including balanced diets and regular exercise, as more effective long-term strategies for weight management compared to quick fixes [12][13]. - A comprehensive approach to weight management may involve a treatment cycle lasting over 20 months, focusing on identifying causes of obesity and designing personalized weight loss strategies [12].